Genelux Corporation, a late clinical-stage immuno-oncology company, has recently published positive Phase I trial results for their drug Olvi-Vec in the journal Frontiers in Immunology. The purpose of the trial was to assess the safety, feasibility, and immune activating effects of administering Olvi-Vec directly into the pleural cavity of patients with malignant pleural effusion (MPE) caused by mesothelioma, lung cancer, or breast cancer. The study took place at the renowned Memorial Sloan Kettering Cancer Center in New York.
The findings from the trial revealed that Olvi-Vec successfully infected tumor cells and led to a reduction in tumor cell density. Additionally, there was an increase in immune cell density, indicating that Olvi-Vec has both direct cytotoxic and immune-activating effects.
In terms of overall survival (OS), the median OS for all patients involved in the trial was 19.5 months. Specifically, patients with malignant pleural mesothelioma (MPM) had a slightly longer median OS of 22 months.